trial

The Effect of Plasma Osmolality on Brain Glutamate

NCTId NCT00611741
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 30 (actual)
Sponsored by Yale University
Primary completion 2011-03
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
30 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2007-03
Primary completion
2011-03
Eligibility
ALL · 21 Years · 45 Years

Interventions & indications

Drugs
furosemide, Na supplements

Sponsors

Yale UniversityLead Sponsor

Investigators

1
Handan Gunduz-Bruce, M.D.Principal Investigator

Sites

1 total
New Haven, United States

Facts & assertions

4 sourced
Enrollment
30
Phase
PHASE1
Primary Completion Date
2011-03
Status
COMPLETED
relationships
The graph out of here
drug
furosemide, Na supplements
drug
lead_sponsor
Yale University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Handan Gunduz-Bruce, M.D.
person